155 related articles for article (PubMed ID: 20712778)
1. Deferasirox--current knowledge and future challenges.
Porter JB
Ann N Y Acad Sci; 2010 Aug; 1202():87-93. PubMed ID: 20712778
[TBL] [Abstract][Full Text] [Related]
2. Iron chelation therapy in MDS: what have we learnt recently?
Schmid M
Blood Rev; 2009 Dec; 23 Suppl 1():S21-5. PubMed ID: 20116636
[TBL] [Abstract][Full Text] [Related]
3. Introduction of higher doses of deferasirox: better efficacy but not effective iron removal from the heart and increased risks of serious toxicities.
Kontoghiorghes GJ
Expert Opin Drug Saf; 2010 Jul; 9(4):633-41. PubMed ID: 20553089
[TBL] [Abstract][Full Text] [Related]
4. Paradoxically increased ferritin level in a beta-thalassemia major patient following the start of deferasirox chelation therapy.
Ricchi P; Ammirabile M; Spasiano A; Costantini S; Cinque P; Di Matola T; Prossomariti L
Acta Haematol; 2010; 123(2):117-20. PubMed ID: 20068283
[TBL] [Abstract][Full Text] [Related]
5. Deferasirox (Exjade) for the treatment of iron overload.
Cappellini MD; Taher A
Acta Haematol; 2009; 122(2-3):165-73. PubMed ID: 19907154
[TBL] [Abstract][Full Text] [Related]
6. Improved efficacy and tolerability of oral deferasirox by twice-daily dosing for patients with transfusion-dependent β-thalassemia.
Chang HH; Lu MY; Liao YM; Lin PC; Yang YL; Lin DT; Chiou SS; Jou ST; Lin KH; Chang TT
Pediatr Blood Cancer; 2011 Mar; 56(3):420-4. PubMed ID: 21072825
[TBL] [Abstract][Full Text] [Related]
7. Update on thalassemia treatment in Taiwan, including bone marrow transplantation, chelation therapy, and cardiomyopathy treatment effects.
Peng CT; Chang JS; Wang LY; Chiou SS; Hsiao CC; Wang SC; Hung GY; Wu KH
Hemoglobin; 2009; 33(5):304-11. PubMed ID: 19814676
[TBL] [Abstract][Full Text] [Related]
8. Treatment with deferasirox (Exjade) effectively decreases iron burden in patients with thalassaemia intermedia: results of a pilot study.
Voskaridou E; Plata E; Douskou M; Papadakis M; Delaki EE; Christoulas D; Terpos E
Br J Haematol; 2010 Jan; 148(2):332-4. PubMed ID: 19863539
[No Abstract] [Full Text] [Related]
9. Improvement in liver pathology of patients with β-thalassemia treated with deferasirox for at least 3 years.
Deugnier Y; Turlin B; Ropert M; Cappellini MD; Porter JB; Giannone V; Zhang Y; Griffel L; Brissot P
Gastroenterology; 2011 Oct; 141(4):1202-11, 1211.e1-3. PubMed ID: 21741344
[TBL] [Abstract][Full Text] [Related]
10. Oral iron chelation and the treatment of iron overload in a pediatric hematology center.
Raphael JL; Bernhardt MB; Mahoney DH; Mueller BU
Pediatr Blood Cancer; 2009 May; 52(5):616-20. PubMed ID: 19148949
[TBL] [Abstract][Full Text] [Related]
11. Deferasirox administration for the treatment of non-transfusional iron overload in patients with thalassaemia intermedia.
Ladis V; Berdousi H; Gotsis E; Kattamis A
Br J Haematol; 2010 Dec; 151(5):504-8. PubMed ID: 20950401
[TBL] [Abstract][Full Text] [Related]
12. Iron chelation with deferasirox for the treatment of secondary hemosiderosis in pediatric oncology patients: a single-center experience.
Ktena YP; Athanasiadou A; Lambrou G; Adamaki M; Moschovi M
J Pediatr Hematol Oncol; 2013 Aug; 35(6):447-50. PubMed ID: 23669734
[TBL] [Abstract][Full Text] [Related]
13. Deferasirox: an update.
Porter JB
Hemoglobin; 2009; 33 Suppl 1():S70-5. PubMed ID: 20001635
[TBL] [Abstract][Full Text] [Related]
14. Coenzyme Q10 levels in β-thalassemia and its association with ferritin levels and chelation therapy.
Karakukcu C; Karakukcu M; Unal E; Patiroglu T; Ozdemir MA; Torun YA; Tang PH
Hemoglobin; 2012; 36(3):219-29. PubMed ID: 22483337
[TBL] [Abstract][Full Text] [Related]
15. Deferasirox: pharmacokinetics and clinical experience.
Galanello R; Campus S; Origa R
Expert Opin Drug Metab Toxicol; 2012 Jan; 8(1):123-34. PubMed ID: 22176640
[TBL] [Abstract][Full Text] [Related]
16. Improvement in hematopoiesis after iron chelation therapy with deferasirox in patients with aplastic anemia.
Lee SE; Yahng SA; Cho BS; Eom KS; Kim YJ; Lee S; Min CK; Kim HJ; Cho SG; Kim DW; Min WS; Park CW; Lee JW
Acta Haematol; 2013; 129(2):72-7. PubMed ID: 23154600
[TBL] [Abstract][Full Text] [Related]
17. Combined iron chelation therapy.
Galanello R; Agus A; Campus S; Danjou F; Giardina PJ; Grady RW
Ann N Y Acad Sci; 2010 Aug; 1202():79-86. PubMed ID: 20712777
[TBL] [Abstract][Full Text] [Related]
18. Long-term efficacy and safety of deferasirox.
Cappellini MD
Blood Rev; 2008 Dec; 22 Suppl 2():S35-41. PubMed ID: 19059055
[TBL] [Abstract][Full Text] [Related]
19. The effects of deferasirox on renal, cardiac and hepatic iron load in patients with β-thalassemia major: preliminary results.
Unal S; Hazirolan T; Eldem G; Gumruk F
Pediatr Hematol Oncol; 2011 Apr; 28(3):217-21. PubMed ID: 21083355
[TBL] [Abstract][Full Text] [Related]
20. Successful chelation therapy with the combination of deferasirox and deferiprone in a patient with thalassaemia major and persisting severe iron overload after single-agent chelation therapies.
Voskaridou E; Christoulas D; Terpos E
Br J Haematol; 2011 Sep; 154(5):654-6. PubMed ID: 21615376
[No Abstract] [Full Text] [Related]
[Next] [New Search]